Specialty Pharma Journal Specialty, Precision & Technology
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Biogen Inc. (NASDAQ: BIIB) today announced that it has agreed to enter into a settlement and license agreement with Forward Pharma, subject to the approval of Forward Pharma’s shareholders and other customary conditions. The license agreement will provide Biogen an irrevocable license to all intellectual property owned by …
Tag Archives: MS
January, 2017
December, 2016
-
22 December
Genentech’s Ocrevus Demonstrates Positive Results in Phase III Multiple Sclorosis Study
December 21, 2016 05:00 PM Eastern Standard Time SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that data from three Phase III studies of its investigational medicine OCREVUS™ (ocrelizumab) – the OPERA I and OPERA II studies in relapsing multiple …
November, 2016
-
16 November
A Hidden Disability
Cognitive changes are a common and disheartening experience for those with multiple sclerosis (MS). Approximately half of MS sufferers report difficulty learning and remembering information, problem solving, focusing, and other high-level cognitive functions. These problems develop because the loss of myelin around nerve fibers interferes with the conveyance of memories …
October, 2016
-
26 October
Diving Deeper with Oral MS Medications
Over the past few years, new oral medications for multiple sclerosis have gained Food and Drug Administration (FDA) approval, giving patients treatment options beyond injectable forms of medication. With multiple sclerosis (MS) medications, one of the primary goals is to extend the time between relapses, which is why these medications …
September, 2016
-
19 September
Novartis’ BAF312 Reduced the Risk of Disability Progression in Late-Stage Multiple Sclerosis Study
Basel, September 17, 2016 – Novartis today announced positive results of the Phase III EXPAND study showing that oral once-daily BAF312 (siponimod) significantly reduced the risk of disability progression compared with placebo in people with secondary progressive multiple sclerosis (SPMS).[1] SPMS is a form of MS characterized by continuous worsening …
-
15 September
New Data Reinforce Efficacy of Zinbryta and Support Long-Term Safety Profile
CAMBRIDGE, Mass. & NORTH CHICAGO, Ill.–(BUSINESS WIRE)–A new post-hoc analysis from the pivotal DECIDE study shows that a significantly greater number of people treated with ZINBRYTATM (daclizumab) achieved no evidence of disease activity (NEDA) compared to those taking AVONEX® (interferon beta-1a) intramuscular injection. The findings continue to support the positive …
-
14 September
Genentech Announces New Late-Stage Data from Three Trials of OCREVUS in MS
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Genentech, a member of the Roche group (SIX: RO, ROG; OTCQX: RHHBY), today announced new analyses from the three OCREVUS™ (ocrelizumab) Phase III studies in relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS) will be presented during the 32nd congress of the European Committee …
-
12 September
iConquerMS Initiative Launches Personalized Medicine Research in Multiple Sclerosis
WALTHAM, Mass., Sept. 12, 2016 /PRNewswire-USNewswire/ — iConquerMS™ (www.iConquerMS.org), a research initiative of the Accelerated Cure Project for Multiple Sclerosis, today launches REAL MS™, a prospective longitudinal study of multiple sclerosis intended to answer important questions about the heterogeneity of the experience of MS across the population of people living …
August, 2016
-
25 August
Novartis’ MS Drug BAF312 Succeeds in Late-Stage Study
Basel, August 25, 2016 – Novartis today announced the Phase III EXPAND study, evaluating the efficacy and safety of oral, once-daily, BAF312 (siponimod) in secondary progressive multiple sclerosis (SPMS), met its primary endpoint of a reduction in the risk of disability progression, compared with placebo. The EXPAND study represents the …
-
12 August
MSAA Launches Online Support Community for Individuals Affected by Multiple Sclerosis
CHERRY HILL, N.J., Aug. 11, 2016 /PRNewswire/ — The Multiple Sclerosis Association of America (MSAA) announces the official launch of My MSAA Community. Powered by HealthUnlocked, this new online community forum has been created to offer people living with multiple sclerosis (MS), care partners, and family members a way to …